IL17A and metabolic dysfunction-associated steatotic liver disease: In line with the present findings, recent research indicates a heightened presence of IL17A variants in MASLD patients experiencing advanced fibrosis, implying that targeting the IL17 pathway could offer therapeutic benefits [24].